Susan Spadt
Nurse Practitioner · Bryn Mawr, PANPI 1578801841
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,578 of the $25,892 with a category attached, or 64.0%. Sumitomo Pharma America, Inc. accounts for 69.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2024 at $18,144 and has fallen 97.2% since, to $517 in 2025. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $264.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$18K
- Myovant Sciences Inc.$4K
- Scynexis, Inc.$2K
- Agile Therapeutics, Inc.$430
- AbbVie$373
- Lupin Inc.$234
- plus $1K from 20 others
What the payments were for
- Consulting fees$16,57864%
- Speaking & faculty fees$2,69210%
- Travel & lodging$4,29517%
- Food & beverage$2,3279%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 9 | $18,015 |
| Myovant Sciences Inc. | 8 | $3,665 |
| Scynexis, Inc. | 7 | $2,111 |
| Agile Therapeutics, Inc. | 1 | $430 |
| AbbVie | 19 | $373 |
| Lupin Inc. | 5 | $234 |
| Bayer | 4 | $174 |
| Johnson & Johnson | 7 | $145 |
| Tolmar, Inc. | 5 | $101 |
| Mayne Pharma Commercial LLC | 2 | $86 |
| Millicent US Inc | 3 | $60 |
| Mission Pharmacal Company | 4 | $59 |
| Boston Scientific | 3 | $59 |
| Bioprotect Medical, Inc. | 1 | $48 |
| Evofem Biosciences, Inc. | 3 | $42 |
| Pfizer | 2 | $41 |
| Amgen | 2 | $39 |
| GSK | 2 | $36 |
| Therapeuticsmd, Inc. | 2 | $33 |
| Procept Biorobotics Corporation | 2 | $28 |
| Duchesnay USA Incorporated | 2 | $28 |
| Merck | 1 | $24 |
| Astellas Pharma US Inc | 1 | $16 |
| Mycovia Pharmaceuticals, Inc. | 1 | $16 |
| Accord Healthcare, Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,892 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EstringEstradiol | 14 | $7,937 |
| Estradiol | 64 | $4,596 |
| Methenamine Hippurate | 25 | $2,083 |
| MenostarEstradiol | 11 | $1,757 |
| Terconazole | 32 | $1,433 |
| Metronidazole | 18 | $841 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 52 | $776 |
| Clobetasol Propionate | 32 | $645 |
| Estradiol (Twice Weekly)Estradiol | 14 | $548 |
| Nystatin | 31 | $541 |
| Fluconazole | 75 | $506 |
| ValacyclovirValacyclovir Hcl | 14 | $436 |
| Mometasone Furoate | 27 | $265 |
| Gabapentin | 25 | $198 |
| Montelukast Sodium | 17 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEstring | $41 | $7,93714 claims |
| BayerMenostar | $174 | $1,75711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Bryn Mawr
- Gina PagottoBryn Mawr$11K
- Awilda RodriguezBryn Mawr$10K
- Kristina BonesteelBryn Mawr$9K
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.